Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SRY
REST API REST API
Homo sapiens
SRY is differentially expressed in 130 experiments: 51 organism parts: blood, heart, ... (49 more);, 89 disease states: normal, "Classic-KS, HIV-, nodular (late) stage", ... (87 more);, 42 cell types 76 cell lines 14 compound treatments and 53 other conditions.
Synonyms TDF
Orthologs SRY_BOVIN (Bos taurus)   (Compare orthologs)
Gene Ontology Term DNA binding, protein binding, nuclear speck, cytoplasm, intracellular membrane-bounded organelle, transcription factor binding, cell differentiation, sex differentiation, nucleus, positive regulation of transcription, DNA-dependent, male sex determination, sequence-specific DNA binding transcription factor activity, positive regulation of male gonad development, sequence-specific distal enhancer binding RNA polymerase II transcription factor activity
InterPro Term HMG_HMG1/HMG2, TF_Sry
UniProt Accession D6QZA4, Q05066, A7WPU8, Q6J4J1, D0VTX2, F5H6J8, F5H3H1
Gene-Disease Assocation 46,XY SEX REVERSAL 1; SRXY1, 46,XX SEX REVERSAL 1; SRXX1
Search EB-eye ENSG00000184895
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-MTAB-24, E-MTAB-25, E-TABM-145, ... (17 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-19639, E-GEOD-22639, E-GEOD-24147, E-GEOD-2450, ... (13 experiments)

Factor Value U/D Experiments
NALM1
1
E-MTAB-37
GA10
1
E-MTAB-37
sk-n-mc cell line, lentivirus treated
1
E-MTAB-62
sk-n-mc cell line; lentivirus treated
1
E-MTAB-62
HeLa
1
E-GEOD-20081
CGTHW1
1
E-MTAB-37
70 more value(s).


Cell type

studied in E-GEOD-10797, E-GEOD-18811, E-AFMX-5, E-MTAB-24, E-GEOD-20033, ... (23 experiments)

Factor Value U/D Experiments
epidermal keratinocyte
1
E-GEOD-2822
embryonic stem cell
1
E-MEXP-930
n/a
1
E-MTAB-24
primary fibroblast
1
E-MEXP-66
iPSC derived from hASC using lentiviral reprogramming vector
1
E-GEOD-20033
platelet
1
E-GEOD-2006
36 more value(s).


Disease state

studied in E-GEOD-5390, E-GEOD-3307, E-GEOD-19743, E-GEOD-2466, E-MEXP-2442, ... (22 experiments)

Factor Value U/D Experiments
normal
3
6
E-GEOD-6338, E-GEOD-2466, E-TABM-702, E-GEOD-8607, E-GEOD-5370, ... (9 experiments)
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
lung adenocarcinoma
2
E-MTAB-37, E-MEXP-231
muscle invasive carcinoma
1
E-GEOD-3167
childhood acute myeloid leukemia
1
E-GEOD-2191
malaria, experimentally infected
1
E-MTAB-62
83 more value(s).


Compound treatment

studied in E-GEOD-3284, E-GEOD-6907, E-GEOD-15205, E-GEOD-412, E-GEOD-5824, ... (8 experiments)

Factor Value U/D Experiments
none
1
2
E-GEOD-412, E-GEOD-5824, E-GEOD-6907
ultrafine particles
1
E-GEOD-4567
N-nitrosodimethylamine
1
E-GEOD-6907
potassium dichromate
1
E-GEOD-6907
arsenic oxide
1
E-GEOD-6907
hydrogen peroxide
1
E-GEOD-5339
8 more value(s).


Biopsy tissue

studied in E-GEOD-5851

Factor Value U/D Experiments
adrenal gland; kidney
1
E-GEOD-5851


Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-3140, E-GEOD-6236, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-321, E-GEOD-21243 ... (5 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2146

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-974, E-GEOD-2466, E-MEXP-2069, ... (23 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-7179

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

organ
studied in E-GEOD-24283

Organism
studied in E-AFMX-1

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19246

RNAi
studied in E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-2508, E-GEOD-2466, E-TABM-311

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Processing time: 0.473 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM